Ligand Income Before Tax vs Reconciled Depreciation Analysis

LGND Stock

USD 86.06 1.04 1.22%

Ligand Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ligand Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ligand Pharmaceuticals is a good investment. Please check the relationship between Ligand Pharmaceuticals Income Before Tax and its Reconciled Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

Income Before Tax vs Reconciled Depreciation

Income Before Tax vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ligand Pharmaceuticals Income Before Tax account and Reconciled Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Ligand Pharmaceuticals' Income Before Tax and Reconciled Depreciation is 0.47. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Ligand Pharmaceuticals Incorporated, assuming nothing else is changed. The correlation between historical values of Ligand Pharmaceuticals' Income Before Tax and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Ligand Pharmaceuticals Incorporated are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Income Before Tax i.e., Ligand Pharmaceuticals' Income Before Tax and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Ligand Pharmaceuticals income statement and is an important metric when analyzing Ligand Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Reconciled Depreciation

Most indicators from Ligand Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

At present, Ligand Pharmaceuticals' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 39.45, whereas Selling General Administrative is forecasted to decline to about 49.7 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	136.1M	140.4M	109.9M	98.8M
Cost Of Revenue	62.2M	52.8M	11.6M	18.5M

Total Operating Expenses Cost Of Revenue

Ligand Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Inventory	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.83	0.62	0.16	0.86	0.71	0.09	0.67	-0.23	0.57	0.76	-0.31	0.83	0.88	0.21	0.84	-0.21	-0.19	0.9	0.56	0.87	-0.01	0.55	-0.39	0.61	-0.39
Short Long Term Debt Total	0.83		0.57	0.17	0.5	0.35	-0.13	0.27	-0.03	0.82	0.35	-0.53	0.92	0.62	0.34	0.9	0.0	0.11	0.95	0.09	0.92	0.01	0.09	-0.24	0.31	-0.22
Other Current Liab	0.62	0.57		0.14	0.4	0.6	0.57	0.31	-0.28	0.1	0.54	-0.26	0.38	0.6	-0.01	0.61	0.07	-0.07	0.65	0.2	0.43	-0.14	0.42	-0.17	0.55	-0.21
Total Current Liabilities	0.16	0.17	0.14		0.1	-0.02	0.22	-0.2	-0.14	0.0	0.25	-0.07	-0.02	0.1	0.35	-0.2	-0.24	0.51	0.1	-0.22	-0.02	0.96	-0.15	-0.18	0.26	-0.21
Total Stockholder Equity	0.86	0.5	0.4	0.1		0.74	0.11	0.88	-0.31	0.31	0.9	-0.1	0.62	0.81	0.07	0.6	-0.33	-0.42	0.67	0.84	0.66	0.0	0.8	-0.42	0.66	-0.42
Property Plant And Equipment Net	0.71	0.35	0.6	-0.02	0.74		0.57	0.74	-0.43	-0.06	0.82	0.11	0.33	0.89	-0.21	0.51	-0.17	-0.47	0.52	0.76	0.4	-0.18	0.83	-0.19	0.75	-0.22
Net Debt	0.09	-0.13	0.57	0.22	0.11	0.57		0.11	-0.15	-0.67	0.51	0.21	-0.39	0.38	-0.17	-0.06	-0.11	-0.08	0.0	0.23	-0.33	0.04	0.47	-0.06	0.66	-0.08
Retained Earnings	0.67	0.27	0.31	-0.2	0.88	0.74	0.11		-0.43	0.14	0.77	0.1	0.45	0.66	-0.36	0.5	-0.1	-0.8	0.47	0.93	0.5	-0.27	0.89	-0.07	0.61	-0.06
Accounts Payable	-0.23	-0.03	-0.28	-0.14	-0.31	-0.43	-0.15	-0.43		0.06	-0.29	-0.51	-0.1	-0.12	0.55	-0.01	-0.05	0.43	-0.05	-0.26	-0.1	-0.14	-0.27	-0.29	-0.25	-0.18
Cash	0.57	0.82	0.1	0.0	0.31	-0.06	-0.67	0.14	0.06		-0.03	-0.52	0.91	0.24	0.35	0.71	0.06	0.13	0.71	-0.06	0.88	-0.02	-0.21	-0.15	-0.14	-0.12
Non Current Assets Total	0.76	0.35	0.54	0.25	0.9	0.82	0.51	0.77	-0.29	-0.03		0.03	0.33	0.82	0.06	0.44	-0.39	-0.35	0.55	0.8	0.39	0.09	0.86	-0.45	0.87	-0.44
Non Currrent Assets Other	-0.31	-0.53	-0.26	-0.07	-0.1	0.11	0.21	0.1	-0.51	-0.52	0.03		-0.46	-0.26	-0.31	-0.45	-0.36	-0.31	-0.47	0.17	-0.48	0.03	0.12	0.02	0.16	0.01
Cash And Short Term Investments	0.83	0.92	0.38	-0.02	0.62	0.33	-0.39	0.45	-0.1	0.91	0.33	-0.46		0.57	0.26	0.9	-0.04	-0.08	0.9	0.27	1.0	-0.12	0.17	-0.26	0.18	-0.25
Net Receivables	0.88	0.62	0.6	0.1	0.81	0.89	0.38	0.66	-0.12	0.24	0.82	-0.26	0.57		0.13	0.7	-0.19	-0.23	0.74	0.67	0.64	-0.07	0.71	-0.36	0.72	-0.36
Common Stock Shares Outstanding	0.21	0.34	-0.01	0.35	0.07	-0.21	-0.17	-0.36	0.55	0.35	0.06	-0.31	0.26	0.13		0.18	-0.53	0.76	0.29	-0.22	0.24	0.31	-0.29	-0.82	-0.03	-0.78
Non Current Liabilities Total	0.84	0.9	0.61	-0.2	0.6	0.51	-0.06	0.5	-0.01	0.71	0.44	-0.45	0.9	0.7	0.18		0.01	-0.2	0.95	0.37	0.91	-0.38	0.36	-0.27	0.39	-0.23
Other Current Assets	-0.21	0.0	0.07	-0.24	-0.33	-0.17	-0.11	-0.1	-0.05	0.06	-0.39	-0.36	-0.04	-0.19	-0.53	0.01		-0.22	-0.07	-0.24	-0.03	-0.23	-0.18	0.72	-0.31	0.71
Other Stockholder Equity	-0.19	0.11	-0.07	0.51	-0.42	-0.47	-0.08	-0.8	0.43	0.13	-0.35	-0.31	-0.08	-0.23	0.76	-0.2	-0.22		-0.07	-0.73	-0.12	0.51	-0.71	-0.38	-0.34	-0.4
Total Liab	0.9	0.95	0.65	0.1	0.67	0.52	0.0	0.47	-0.05	0.71	0.55	-0.47	0.9	0.74	0.29	0.95	-0.07	-0.07		0.33	0.92	-0.1	0.35	-0.34	0.49	-0.31
Property Plant And Equipment Gross	0.56	0.09	0.2	-0.22	0.84	0.76	0.23	0.93	-0.26	-0.06	0.8	0.17	0.27	0.67	-0.22	0.37	-0.24	-0.73	0.33		0.32	-0.28	0.95	-0.26	0.63	-0.24
Total Current Assets	0.87	0.92	0.43	-0.02	0.66	0.4	-0.33	0.5	-0.1	0.88	0.39	-0.48	1.0	0.64	0.24	0.91	-0.03	-0.12	0.92	0.32		-0.13	0.24	-0.26	0.24	-0.25
Short Term Debt	-0.01	0.01	-0.14	0.96	0.0	-0.18	0.04	-0.27	-0.14	-0.02	0.09	0.03	-0.12	-0.07	0.31	-0.38	-0.23	0.51	-0.1	-0.28	-0.13		-0.27	-0.1	0.08	-0.13
Inventory	0.55	0.09	0.42	-0.15	0.8	0.83	0.47	0.89	-0.27	-0.21	0.86	0.12	0.17	0.71	-0.29	0.36	-0.18	-0.71	0.35	0.95	0.24	-0.27		-0.2	0.75	-0.19
Common Stock Total Equity	-0.39	-0.24	-0.17	-0.18	-0.42	-0.19	-0.06	-0.07	-0.29	-0.15	-0.45	0.02	-0.26	-0.36	-0.82	-0.27	0.72	-0.38	-0.34	-0.26	-0.26	-0.1	-0.2		-0.26	0.98
Short Term Investments	0.61	0.31	0.55	0.26	0.66	0.75	0.66	0.61	-0.25	-0.14	0.87	0.16	0.18	0.72	-0.03	0.39	-0.31	-0.34	0.49	0.63	0.24	0.08	0.75	-0.26		-0.19
Common Stock	-0.39	-0.22	-0.21	-0.21	-0.42	-0.22	-0.08	-0.06	-0.18	-0.12	-0.44	0.01	-0.25	-0.36	-0.78	-0.23	0.71	-0.4	-0.31	-0.24	-0.25	-0.13	-0.19	0.98	-0.19

Click cells to compare fundamentals

Ligand Pharmaceuticals Account Relationship Matchups

Ligand Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.5B	1.4B	1.3B	762.7M	833.1M	453.0M
Short Long Term Debt Total	648.9M	454.5M	336.3M	87.7M	6.2M	5.9M
Other Current Liab	11.2M	60.3M	22.2M	21.0M	256K	243.2K
Total Current Liabilities	17.0M	100.1M	41.7M	98.8M	16.8M	15.9M
Total Stockholder Equity	767.2M	709.5M	821.6M	597.5M	700.9M	736.0M
Property Plant And Equipment Net	10.4M	22.7M	32.7M	15.0M	9.5M	8.3M
Net Debt	(362.6M)	406.9M	316.7M	87.7M	(16.8M)	(15.9M)
Retained Earnings	400.1M	392.0M	449.1M	450.9K	503.0M	528.2M
Accounts Payable	2.4M	3.8M	8.4M	5.3K	14.9M	11.9M
Cash	1.0B	47.6M	19.5M	45.0K	23.0M	21.8M
Non Current Assets Total	345.7M	861.7M	836.6M	499.1M	595.6M	625.4M
Non Currrent Assets Other	9.5M	18.7M	23.3M	14.2M	21.5M	22.6M
Cash And Short Term Investments	1.1B	411.2M	341.1M	211.9M	170.3M	177.7M
Net Receivables	41.7M	59.1M	91.6M	35.0M	39.3M	22.8M
Common Stock Shares Outstanding	19.8M	16.2M	17.2M	16.9M	17.8M	16.2M
Liabilities And Stockholders Equity	1.5B	1.4B	1.3B	762.7M	833.1M	453.0M
Non Current Liabilities Total	685.1M	552.6M	438.1M	66.4M	113.9M	180.2M
Other Current Assets	4.7M	3.8M	4.7M	3.4M	3.8M	3.6M
Other Stockholder Equity	367.3M	318.4M	373.4M	597.0M	198.7M	188.8M
Total Liab	702.1M	652.8M	479.8M	165.2M	130.7M	256.0M
Property Plant And Equipment Gross	17.5M	21.3M	32.7M	15.0M	31.7M	33.3M
Total Current Assets	1.1B	500.6M	464.8M	263.6M	237.4M	218.7M
Accumulated Other Comprehensive Income	(216K)	(801K)	(917K)	(984.0)	(817K)	(857.9K)
Short Term Debt	1.2M	6.6M	46K	77.4M	410K	389.5K
Inventory	7.3M	26.5M	27.3M	13.3M	24.0M	25.2M
Short Term Investments	58.3M	363.6M	321.6M	166.9K	147.4M	154.7M
Other Liab	61.8M	104.7M	101.9M	56.0M	64.4M	43.3M
Other Assets	28.0M	62.3M	58.8M	13.3M	15.3M	14.5M
Long Term Debt	609.9M	639.0M	442.3M	320.7M	368.8M	387.3M
Intangible Assets	20.1M	11.0M	10.1M	10.2M	366.9M	385.2M
Property Plant Equipment	7.2M	14.4M	32.7M	27.5M	31.6M	33.2M
Current Deferred Revenue	2.1M	29.4M	11.0M	355K	1.2M	1.2M
Good Will	305.7M	785.0M	735.0M	448.1M	103.4M	98.2M
Retained Earnings Total Equity	(229.2M)	400.1M	392.0M	449.1M	516.5M	542.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:

How To Invest In Ligand

Details

Is Ligand Stock a good investment?

Details

What is Ligand Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Ligand Stock analysis

When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Transaction History View history of all your transactions and understand their impact on performance
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

Is Ligand Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.032

Earnings Share

5.35

Revenue Per Share

6.774

Quarterly Revenue Growth

(0.30)

Return On Assets

(0)

The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ligand Income Before Tax vs Reconciled Depreciation Analysis

Income Before Tax vs Reconciled Depreciation

Income Before Tax vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Income Before Tax

Reconciled Depreciation

Ligand Pharmaceuticals fundamental ratios Correlations

Ligand Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ligand Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Ligand Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 0.98	Common Stock Total Equity
Short Term Debt	+ 0.96	Total Current Liabilities
Total Liab	+ 0.95	Short Long Term Debt Total
Total Liab	+ 0.95	Non Current Liabilities Total
Inventory	+ 0.95	Property Plant And Equipment Gross

Common Stock Total Equity	- 0.82	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.8	Retained Earnings
Common Stock	- 0.78	Common Stock Shares Outstanding
Property Plant And Equipment Gross	- 0.73	Other Stockholder Equity
Inventory	- 0.71	Other Stockholder Equity
Cash	- 0.67	Net Debt